TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib

COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune prof...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of microbiology, immunology and infection immunology and infection, 2020-06, Vol.53 (3), p.368-370
Hauptverfasser:	Wu, Dandan, Yang, Xuexian O.
Format:	Artikel
Sprache:	eng
Schlagworte:	Betacoronavirus - immunology Coronavirus Infections - drug therapy Coronavirus Infections - pathology COVID-19 Cytokine Release Syndrome - drug therapy Cytokine storm Cytokines - biosynthesis Cytokines - immunology Humans JAK2 inhibitor Janus Kinase 2 - antagonists & inhibitors Pandemics Pneumonia, Viral - drug therapy Pneumonia, Viral - pathology Pyrrolidines - pharmacology SARS-CoV-2 Sulfonamides - pharmacology TH17 Th17 Cells - immunology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.
ISSN:	1684-1182 1995-9133
DOI:	10.1016/j.jmii.2020.03.005